MicroRNA (miRNAs) Market: Current Analysis and Forecast (2021-2027)

At present, there are over 2000 MicroRNA (miRNAs) discovered in humans that helps in the regulation of gene expression. Most of the human disease occurs due to genetic changes, hence miRNA is considered to be an important part of clinical diagnostics and therapeutic agents. MicroRNA (miRNA)-based therapeutics can be divided into miRNA mimics and inhibitors of miRNAs (antimiRs). For instance, miR-34a is a miRNA mimic that targets the BCL2, MET, MYC, CDK6, and other genes for the treatment of solid tumors (e.g., lung, liver, colon, brain, prostate, pancreatic, bladder, and cervical), Myeloma, and B cell lymphoma.
The demand for miRNA is mainly increasing on account of the emerging microRNA (miRNA) tools for disease-associated applications, the high role of miRNA in the target identification and prediction, and the high adoption of miRNA as a potential biomarker. Moreover, the role of miRNA in the diagnosis and treatment of various chronic diseases such as cancer, neurological disease, liver disease, metabolic diseases, and chronic heart diseases is also propelling the market growth. The overexpressed miRNA in certain diseases is known as oncogenes while the under-expressed miRNA in certain diseases is known as tumor suppressor miRNA. For instance, miRNA-212 functions as a tumor suppressor in colorectal carcinoma through targeting SOX4.
Insights Presented in the Report
“Amongst Products, Instruments segment holds the major share.”
Based on Products, the market is fragmented into Instruments and Consumables. The instruments segment holds the largest share in 2020 and is expected to register the highest CAGR in the upcoming period. In the recent few years, there is an increase in the number of miRNA-based clinical trials coupled with the rising incidents of chronic diseases. The various instruments are required in the completion of miRNA-based clinical trials such as TransmiR, DIANA-mirGen v.3 which is propelling the segment growth in the market.
“Amongst Services, Service Type segment is anticipated to grow at the highest CAGR during the analyzed period.”
Based on Services, the market is fragmented into Service Type and Specimen. The Service Type segment holds the largest share in 2020 and is expected to register the highest CAGR in the upcoming period owing to the rising strategic collaboration between companies for providing microRNA profiling services. For instance, LC Sciences announced its strategic collaboration with DNAVision to increase accessibility to its custom microRNA profiling service and enhance both its customer and technical service to researchers in Europe.
“Amongst Applications, Cancer segment is anticipated to grow at the highest CAGR during the analyzed period.”
Based on Applications, the market is fragmented into Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Disease, Neurological Disease, and Others. The Cancer segment holds the largest share in 2020 and is expected to register the highest CAGR in the upcoming period owing to the rising clinical trials of miRNA in the treatment of cancer coupled with the rising prevalence of cancer cases. As per the International Agency for Research on Cancer (IARC) 1 in 5 people develop cancer during their lifetime globally and 1 in 8 men and 1 in 11 women die from cancer.
“Amongst End-user, Biotechnology & Pharmaceutical Companies segment is anticipated to grow at the highest CAGR during the analyzed period.”
Based on End-user, the market is fragmented into Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Other end-users. The Biotechnology & Pharmaceutical Companies segment holds the largest share in 2020 and is expected to register the highest CAGR in the upcoming period due to a rise in research funding for new startups. For instance, Twentyeight-Seven Therapeutics (28-7), a biotechnology company focused on modulating non-coding RNA (ncRNA) biology to develop treatments for cancer and other diseases, announced the successful completion of its $65 million Series A financing in 2018. The funding will be used to advance 28-7’s lead program, aimed at the discovery and development of small molecules that increase the levels of the tumor suppressor microRNA (miRNA), Let-7, into serious cancer indications.
“North America signifies one of the largest markets and Europe is expected to be the fastest-growing markets of MiRNA market.”
For a better understanding of the market adoption of miRNA, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America will dominate the miRNA market on account of the rising number of clinical trials for the development of novel therapeutics, and the increase in recent product launches in the region. In September 2016, Amgen and Arrowhead Pharmaceuticals signed two licensing and collaboration deals to develop miRNA-based therapies for cardiovascular diseases. Some of the major players operating in the market include Merck KGaA, Thermo Fisher Scientific, Inc., Horizon Discovery Ltd., Synlogic, QIAGEN, GeneCopoeia, Inc., New England Biolabs, Quantabio, NanoString, and BioGenex. Several M&As along with partnerships have been undertaken by these players to boost their presence in different regions.
Reasons to buy this report:
• The study includes market sizing and forecasting analysis validated by authenticated key industry experts
• The report presents a quick review of overall industry performance at one glance
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry
• The study comprehensively covers the market across different segments
• Deep dive regional level analysis of the industry
Customization Options:
The miRNA market can further be customized as per the requirement or any other market segment. Besides this, understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.